Exelixis, Inc. (0IJO.L)
USD 34.24
(-1.28%)
USD 34.24
(-1.28%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.75 Billion USD | 13.17% |
| 2022 | 1.55 Billion USD | 12.38% |
| 2021 | 1.38 Billion USD | 45.29% |
| 2020 | 951.26 Million USD | 1.77% |
| 2019 | 934.67 Million USD | 12.96% |
| 2018 | 827.47 Million USD | 89.18% |
| 2017 | 437.41 Million USD | 136.56% |
| 2016 | 184.9 Million USD | 455.65% |
| 2015 | 33.27 Million USD | 44.26% |
| 2014 | 23.06 Million USD | -23.67% |
| 2013 | 30.22 Million USD | -36.31% |
| 2012 | 47.45 Million USD | -83.62% |
| 2011 | 289.63 Million USD | 56.52% |
| 2010 | 185.04 Million USD | 21.93% |
| 2009 | 151.75 Million USD | 28.76% |
| 2008 | 117.85 Million USD | 4.05% |
| 2007 | 113.26 Million USD | 15.76% |
| 2006 | 97.85 Million USD | 30.68% |
| 2005 | 74.87 Million USD | 43.77% |
| 2004 | 52.07 Million USD | 1.04% |
| 2003 | 51.54 Million USD | 16.29% |
| 2002 | 44.32 Million USD | 8.09% |
| 2001 | 41 Million USD | -5.42% |
| 2000 | 43.35 Million USD | 167.63% |
| 1999 | 16.2 Million USD | 613.03% |
| 1998 | 2.27 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 619.51 Million USD | 53.36% |
| 2024 Q3 | 460.73 Million USD | -15.71% |
| 2024 Q1 | 403.97 Million USD | -11.78% |
| 2023 FY | 1.75 Billion USD | 13.17% |
| 2023 Q3 | 453.14 Million USD | 0.22% |
| 2023 Q2 | 452.14 Million USD | 14.62% |
| 2023 Q1 | 394.47 Million USD | -3.31% |
| 2023 Q4 | 457.89 Million USD | 1.05% |
| 2022 Q2 | 405.94 Million USD | 18.43% |
| 2022 Q1 | 342.77 Million USD | -21.78% |
| 2022 Q3 | 396.43 Million USD | -2.34% |
| 2022 Q4 | 407.99 Million USD | 2.92% |
| 2022 FY | 1.55 Billion USD | 12.38% |
| 2021 FY | 1.38 Billion USD | 45.29% |
| 2021 Q1 | 257.03 Million USD | -1.53% |
| 2021 Q2 | 370.29 Million USD | 44.06% |
| 2021 Q4 | 438.22 Million USD | 38.44% |
| 2021 Q3 | 316.54 Million USD | -14.51% |
| 2020 Q2 | 250.25 Million USD | 14.99% |
| 2020 Q3 | 222.36 Million USD | -11.14% |
| 2020 Q4 | 261.01 Million USD | 17.38% |
| 2020 FY | 951.26 Million USD | 1.77% |
| 2020 Q1 | 217.62 Million USD | -5.29% |
| 2019 Q1 | 207.98 Million USD | -6.0% |
| 2019 FY | 934.67 Million USD | 12.96% |
| 2019 Q4 | 229.79 Million USD | -13.01% |
| 2019 Q3 | 264.16 Million USD | 13.5% |
| 2019 Q2 | 232.73 Million USD | 11.9% |
| 2018 Q1 | 206.7 Million USD | 78.38% |
| 2018 FY | 827.47 Million USD | 89.18% |
| 2018 Q4 | 221.25 Million USD | 1.47% |
| 2018 Q3 | 218.03 Million USD | 21.06% |
| 2018 Q2 | 180.11 Million USD | -12.87% |
| 2017 Q4 | 115.88 Million USD | -21.62% |
| 2017 Q1 | 77.68 Million USD | 2.58% |
| 2017 FY | 437.41 Million USD | 136.56% |
| 2017 Q3 | 147.85 Million USD | 54.02% |
| 2017 Q2 | 95.99 Million USD | 23.57% |
| 2016 Q3 | 59.73 Million USD | 72.2% |
| 2016 Q1 | 14.74 Million USD | 65.36% |
| 2016 FY | 184.9 Million USD | 455.65% |
| 2016 Q4 | 75.72 Million USD | 26.77% |
| 2016 Q2 | 34.69 Million USD | 135.33% |
| 2015 Q2 | 7.3 Million USD | -15.26% |
| 2015 FY | 33.27 Million USD | 44.26% |
| 2015 Q4 | 8.91 Million USD | 5.7% |
| 2015 Q3 | 8.43 Million USD | 15.44% |
| 2015 Q1 | 8.62 Million USD | 29.28% |
| 2014 FY | 23.06 Million USD | -23.67% |
| 2014 Q4 | 6.66 Million USD | 16.63% |
| 2014 Q3 | 5.71 Million USD | -6.03% |
| 2014 Q2 | 6.08 Million USD | 32.4% |
| 2014 Q1 | 4.59 Million USD | 12.54% |
| 2013 FY | 30.22 Million USD | -36.31% |
| 2013 Q4 | 4.08 Million USD | -21.1% |
| 2013 Q3 | 5.17 Million USD | -55.27% |
| 2013 Q2 | 11.57 Million USD | 23.24% |
| 2013 Q1 | 9.38 Million USD | 20.16% |
| 2012 Q4 | 7.81 Million USD | -41.31% |
| 2012 FY | 47.45 Million USD | -83.62% |
| 2012 Q1 | 18.51 Million USD | -80.16% |
| 2012 Q2 | 7.81 Million USD | -57.79% |
| 2012 Q3 | 13.31 Million USD | 70.4% |
| 2011 Q4 | 93.3 Million USD | -27.26% |
| 2011 FY | 289.63 Million USD | 56.52% |
| 2011 Q3 | 128.27 Million USD | 298.83% |
| 2011 Q2 | 32.16 Million USD | -10.39% |
| 2011 Q1 | 35.89 Million USD | -11.98% |
| 2010 Q2 | 47.59 Million USD | 12.79% |
| 2010 Q4 | 40.77 Million USD | -25.15% |
| 2010 Q3 | 54.47 Million USD | 14.45% |
| 2010 Q1 | 42.19 Million USD | -4.26% |
| 2010 FY | 185.04 Million USD | 21.93% |
| 2009 Q1 | 23.5 Million USD | -20.51% |
| 2009 Q4 | 44.07 Million USD | -15.25% |
| 2009 Q3 | 52.01 Million USD | 101.88% |
| 2009 Q2 | 25.76 Million USD | 9.61% |
| 2009 FY | 151.75 Million USD | 28.76% |
| 2008 Q2 | 30.41 Million USD | 8.83% |
| 2008 Q1 | 27.94 Million USD | -3.8% |
| 2008 FY | 117.85 Million USD | 4.05% |
| 2008 Q4 | 29.57 Million USD | -1.21% |
| 2008 Q3 | 29.93 Million USD | -1.58% |
| 2007 Q4 | 29.04 Million USD | 8.49% |
| 2007 Q2 | 29.18 Million USD | 4.0% |
| 2007 Q1 | 28.06 Million USD | -71.32% |
| 2007 FY | 113.26 Million USD | 15.76% |
| 2007 Q3 | 26.77 Million USD | -8.27% |
| 2006 Q1 | 17.84 Million USD | -76.16% |
| 2006 Q4 | 97.85 Million USD | 315.68% |
| 2006 Q3 | 23.54 Million USD | -13.58% |
| 2006 Q2 | 27.24 Million USD | 52.63% |
| 2006 FY | 97.85 Million USD | 30.68% |
| 2005 Q3 | 14.4 Million USD | -58.03% |
| 2005 Q1 | 12.87 Million USD | -75.28% |
| 2005 Q4 | 74.87 Million USD | 419.97% |
| 2005 FY | 74.87 Million USD | 43.77% |
| 2005 Q2 | 34.31 Million USD | 166.51% |
| 2004 Q3 | 12.66 Million USD | 0.82% |
| 2004 Q2 | 12.55 Million USD | 5.61% |
| 2004 FY | 52.07 Million USD | 1.04% |
| 2004 Q1 | 11.89 Million USD | -13.61% |
| 2004 Q4 | 52.07 Million USD | 311.29% |
| 2003 Q1 | 12.33 Million USD | -0.99% |
| 2003 Q2 | 13 Million USD | 5.47% |
| 2003 Q3 | 12.43 Million USD | -4.35% |
| 2003 FY | 51.54 Million USD | 16.29% |
| 2003 Q4 | 13.76 Million USD | 10.67% |
| 2002 Q1 | 11.56 Million USD | -9.64% |
| 2002 Q4 | 12.45 Million USD | 19.4% |
| 2002 FY | 44.32 Million USD | 8.09% |
| 2002 Q3 | 10.43 Million USD | 5.39% |
| 2002 Q2 | 9.89 Million USD | -14.39% |
| 2001 Q3 | 11.92 Million USD | 39.49% |
| 2001 Q2 | 8.55 Million USD | -9.78% |
| 2001 Q1 | 9.47 Million USD | -10.46% |
| 2001 Q4 | 12.79 Million USD | 7.25% |
| 2001 FY | 41 Million USD | -5.42% |
| 2000 Q4 | 10.58 Million USD | -2.86% |
| 2000 Q1 | 9.99 Million USD | 0.0% |
| 2000 Q2 | 11.87 Million USD | 18.78% |
| 2000 FY | 43.35 Million USD | 167.63% |
| 2000 Q3 | 10.89 Million USD | -8.24% |
| 1999 FY | 16.2 Million USD | 613.03% |
| 1998 FY | 2.27 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Editas Medicine, Inc. | -99.52 Million USD | 1865.997% |
| Dynavax Technologies Corporation | 182.11 Million USD | -865.127% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | -235.597% |
| Perrigo Company plc | 1.68 Billion USD | -4.598% |
| Illumina, Inc. | 2.74 Billion USD | 35.945% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 88.455% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 18474.043% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 93.373% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 66.45% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -17403.097% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 84.447% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 9022.59% |
| Waters Corporation | 1.76 Billion USD | 0.201% |
| Biogen Inc. | 7.3 Billion USD | 75.93% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 3977.906% |
| Evolus, Inc. | 140.52 Million USD | -1150.773% |
| Adicet Bio, Inc. | -6.09 Million USD | 28923.565% |
| Cara Therapeutics, Inc. | 14.79 Million USD | -11780.904% |
| bluebird bio, Inc. | -4.03 Million USD | 43714.417% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -2305.547% |
| FibroGen, Inc. | 128.9 Million USD | -1263.543% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 49.274% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 5739.374% |
| Homology Medicines, Inc. | -7.22 Million USD | 24414.027% |
| Geron Corporation | -123.5 Million USD | 1523.173% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | -15.797% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | -385.501% |
| Myriad Genetics, Inc. | 476.4 Million USD | -268.946% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 602038.699% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 540.744% |
| Zoetis Inc. | 5.83 Billion USD | 69.872% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -581906.954% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 18.967% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 7.704% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 79.579% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 580186.139% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | -125.771% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 561653.035% |
| Verastem, Inc. | -62 Thousand USD | 2835037.097% |
| Nektar Therapeutics | 53.47 Million USD | -3186.699% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | -618.777% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 2162.595% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | -60.812% |
| OPKO Health, Inc. | 318.12 Million USD | -452.503% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 4.858% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | -269.339% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 2.21 Million USD | -79252.641% |
| Imunon, Inc. | -720 Thousand USD | 244217.888% |
| Blueprint Medicines Corporation | 236.58 Million USD | -642.933% |
| Insmed Incorporated | 239.63 Million USD | -633.474% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | -175.975% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | -10048.744% |
| TG Therapeutics, Inc. | 219.1 Million USD | -702.189% |
| Incyte Corporation | 3.44 Billion USD | 48.915% |
| Emergent BioSolutions Inc. | 343.9 Million USD | -411.097% |